<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00353717</url>
  </required_header>
  <id_info>
    <org_study_id>cpblb1-HMO-CTIL</org_study_id>
    <nct_id>NCT00353717</nct_id>
  </id_info>
  <brief_title>Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma</brief_title>
  <official_title>Phase II of Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Basal like breast carcinoma is a Her2, estrogen receptor (ER) progesterone receptor (PR)
      negative breast cancer. It is notable for the high level of epidermal growth factor receptor
      (EGFR) expression in this tumor subtype .

      Thus the investigators wanted to combine the use of anti EGFR therapy in the form of Erbitux
      (cetuximab) with the widely used weekly taxol chemotherapy for the treatment of these women.
      This is a small phase I/II study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Basal like breast carcinoma is a Her2, ER PR negative breast cancer. It is notable for the
      high percentage of EGFR expression in this tumor subtype.Weekly taxol (paclitaxel) is widely
      used in breast cancer patients with metastatic disease. Erbitux (cetuximab) is a monoclonal
      antibody that shown its ability to enhance activity of chemotherapy in colon carcinoma. Thus
      we wanted to combine the use of anti EGFR therapy in the form of Erbitux (cetuximab) with the
      widely used weekly taxol chemotherapy for the treatment of women with basal like breast
      carcinoma. This is a small phase II study that will hopefully provide initial data as to the
      general tolerability and response rate of this combination in this disease. Furthermore,
      pathologic analysis will be used to try and assess relation of response with the presence of
      immunohistochemical markers such as EGFR expression.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2006</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor markers tumor size by ct</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab paclitaxel</intervention_name>
    <description>weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2</description>
    <arm_group_label>1</arm_group_label>
    <other_name>weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metastatic breast carcinoma of the basal like subtype with available
             biopsy for analysis and ECOG PS of 2 or less

        Exclusion Criteria:

          -  Pregnancy

          -  BUN, blood creatinine, AST, ALT &gt; X3 of upper limits of normal

          -  More than previous 2 chemotherapy lines in the metastatic settings or the use of
             previous inhibitors of EGFR
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hovav Nechushtan, MD/PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Ein Kerem Jerusalem</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tamar Peretz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Ein Kerem</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hovav Nechushtan, MD/PhD</last_name>
    <phone>972-0508946057</phone>
    <email>hovavnech@hadassah.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tamar Peretz, MD</last_name>
    <phone>972-2 6777825</phone>
    <email>tamiy@hadassah.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncology Department Hadassah Ein Kerem POB 12000</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tamar Peretz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004 Aug 15;10(16):5367-74.</citation>
    <PMID>15328174</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2006</study_first_submitted>
  <study_first_submitted_qc>July 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2006</study_first_posted>
  <last_update_submitted>January 12, 2009</last_update_submitted>
  <last_update_submitted_qc>January 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr Hovav Nechushtan</name_title>
    <organization>Hadassah Hebrew university medical center</organization>
  </responsible_party>
  <keyword>breast</keyword>
  <keyword>basal like</keyword>
  <keyword>carcinoma</keyword>
  <keyword>metastatic</keyword>
  <keyword>EGFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

